GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RUA Life Sciences PLC (FRA:AOHA) » Definitions » Debt-to-EBITDA

RUA Life Sciences (FRA:AOHA) Debt-to-EBITDA : -0.49 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is RUA Life Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

RUA Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.14 Mil. RUA Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.32 Mil. RUA Life Sciences's annualized EBITDA for the quarter that ended in Mar. 2024 was €-0.93 Mil. RUA Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.49.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RUA Life Sciences's Debt-to-EBITDA or its related term are showing as below:

FRA:AOHA' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.32   Med: -0.25   Max: -0.17
Current: -0.25

During the past 13 years, the highest Debt-to-EBITDA Ratio of RUA Life Sciences was -0.17. The lowest was -0.32. And the median was -0.25.

FRA:AOHA's Debt-to-EBITDA is ranked worse than
100% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.34 vs FRA:AOHA: -0.25

RUA Life Sciences Debt-to-EBITDA Historical Data

The historical data trend for RUA Life Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RUA Life Sciences Debt-to-EBITDA Chart

RUA Life Sciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.32 -0.17 -0.24 -0.25

RUA Life Sciences Semi-Annual Data
Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.20 -0.24 -0.24 -0.19 -0.49

Competitive Comparison of RUA Life Sciences's Debt-to-EBITDA

For the Medical Devices subindustry, RUA Life Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RUA Life Sciences's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RUA Life Sciences's Debt-to-EBITDA falls into.



RUA Life Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RUA Life Sciences's Debt-to-EBITDA for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.137 + 0.318) / -1.839
=-0.25

RUA Life Sciences's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.137 + 0.318) / -0.93
=-0.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Mar. 2024) EBITDA data.


RUA Life Sciences  (FRA:AOHA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


RUA Life Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RUA Life Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


RUA Life Sciences Business Description

Traded in Other Exchanges
Address
2 Drummond Crescent, Ayrshire, Scotland, Irvine, GBR, KA11 5AN
RUA Life Sciences PLC is a biomedical polymer technology, components, and medical device company. The company's principal activities comprise exploiting the value of its IP and know-how, medical device contract manufacturing, and development of cardiovascular devices. Its business segments are Royalty and License Income (Biomaterials), Contract Manufacture, Product Development (Vascular), and Product Innovation (Structural Heart). It derives the majority of its revenue from the Contract Manufacture segment. Geographically, it derives the majority of its revenue from the USA and has a presence in Switzerland, Italy, the UK, and Israel.

RUA Life Sciences Headlines

No Headlines